Douglas L Boggs
Pharm.D., M.S.
|
| Academic Title:
Research Associate |
| Primary Appointment:
Psychiatry |
|
dboggs@mprc.umaryland.edu |
| Location:
MPRC,
55 Wade Avenue, Catonsville, MD 21228 |
| Phone:
(410) 402-6818 |
| Fax:
(410) 402-6880 |
|
Personal History
Education
1999: B.S., Food Science and Human Nutrition, University of Florida, Gainesville, FL
2003: PharmD, University of Florida, Gainesville, FL
2005: M.S., Pharmacy Practice, University of Texas, Austin, TX
Positions/Training
2003 - 2005: Psychiatric Pharmacy Residency, University of Texas Health Science Center, San Antonio, San Antonio, TX
2005 - 2007: T-32 Fellowship at the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD
2007 - Present: Faculty Research Associate at the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD
2007: Board Certification in Psychiatric Pharmacy Practice (BCPP)
Honors
2007: NCDEU New Investigator Award, (NIMH)
Research Interests
* New pharmacological treatments for schizophrenia
* Co-morbid mental illness and substance abuse
* Effects of cannabis
* Transcranial Magnetic Stimulation
Lab Techniques and Equipment
Transcranial Magnetic Stimulation
Publications
Kelly DL, Boggs DL, Conley RR. Reaching for Wellness in Schizophrenia. Psychiatr Clin N Am 2007;31(3): 453-79 PMID: 17720032
McMahon RP, Kelly DL, Boggs DL, Li L, Hu Q, Davis JM, Carpenter WT. Feasibility of Reducing the Duration of Placebo-Controlled Trials in Schizophrenia Research. (on-line: January 8, 2008) Schizophr Bull 2008; 34(2): 292-301 PMID: 18184634
Boggs DL, Kelly DL, Love RC, McMahon RP, Conley RR. Comparison of Clozapine Response for Inpatients in the Research Setting versus Routine Clinical Practice. (on-line: January 24, 2008) Psychiatr Q 2008; 79(2): 111-9 PMID: 18214677
Boggs DL, Kelly DL, Nelson MW, Yu Y, Feldman S, McMahon RP, Conley RR. Quetiapine at High Doses for the Treatment of Refractory Schizophrenia.(letter) (on-line: February 20, 2008) Schizophr Res 2008; 101(1-3): 347-8 PMID: 18281197
Kelly DL, McMahon RP, Weiner E, Boggs DL, Dickinson D, Conley RR, Buchanan RW. Lack of Beneficial Galantamine Effect for Smoking Behavior: A Double-Blind Randomized Trial in People with Schizophrenia. (on-line: June11, 2008) Schizophr Res 2008; 103(1-3): 161-8 PMID: 18550339
Conley RR, Boggs DL, Kelly DL, McMahon RP, Dickinson D, Feldman S, Ball MP, Buchanan RW. The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia. Clin Neuropharmacol 2009; 32(2):69-74 PMID: 18978489
Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Dickinson D, Nelson M, Gold JM, Ball MP, Feldman S, Liu F, Conley RR. Atomoxetine for Cognitive Impairments in People with Schizophrenia. (on-line: April 7, 2009) J Clin Psychiatry 2009 ;70(4):518-25 PMID: 19358788
Kelly DL, Feldman S, Boggs DL, Gale E, Conley RR. Nonresponse to Clozapine and Premorbid Functioning in Treatment Refractory Schizophrenia. Compr Psychiatry (on-line: August 27, 2009).
Faculty members:
Click here to update your contact information and create a profile.
|